PMID- 29318957
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Print)
IS  - 1557-9883 (Linking)
VI  - 12
IP  - 4
DP  - 2018 Jul
TI  - Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, 
      Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
PG  - 900-906
LID - 10.1177/1557988317750989 [doi]
AB  - Our research objective is to understand more, through subjective, self-reports on 
      discussion boards/forums, persons' experiences associated with the use of drugs 
      that alter androgen metabolism, such as finasteride. Finasteride is an orally 
      active, specific inhibitor of 5alpha-reductase, which is localized to many 
      androgen-dependent tissues. Finasteride inhibits the conversion of testosterone 
      (T) to dihydrotestosterone (DHT), and is commonly used to treat benign prostatic 
      hypertrophy (BPH) and male pattern baldness (MPB), both disorders associated with 
      elevated DHT levels and 5alpha-reductase activity in the prostate and hair follicles, 
      respectively. It is now acknowledged that long-term use and discontinuation of 
      finasteride has adverse effects (AEs); however, these claims have not been well 
      documented. In this study, discussion board posts (forums) were analyzed as 
      self-reports of what finasteride users indicate is problematic for them. Reports 
      were categorized by the age of subjects as well as the types of AEs described: 
      antiandrogenic, estrogenic, central, and nonspecific/severe. A total of 244 cases 
      were recorded and analyzed on the discussion forum on propeciahelp.com . Among 
      these, 74 (32%) cases reported antiandrogenic affects, 43 (19%) reported 
      estrogenic effects, 70 (30%) reported central effects, 11 (5%) reported 
      nonspecific/severe AEs, and 31 (14%) reported AEs in all categories. The 
      categorization of AEs may prompt further investigation into the pathophysiology 
      of post-finasteride syndrome (PFS). Also, subjective reports may engender greater 
      understanding of the perceived lasting AEs of finasteride.
FAU - Walf, Alicia A
AU  - Walf AA
AD  - 1 Departments of Psychology, The University at Albany-SUNY, Albany, NY, USA.
AD  - 2 Department of Cognitive Science, Rensselaer, Troy, NY, USA.
FAU - Kaurejo, Shan
AU  - Kaurejo S
AD  - 1 Departments of Psychology, The University at Albany-SUNY, Albany, NY, USA.
FAU - Frye, Cheryl A
AU  - Frye CA
AD  - 1 Departments of Psychology, The University at Albany-SUNY, Albany, NY, USA.
AD  - 3 The Centers for Life Sciences, The University at Albany-SUNY, Albany, NY, USA.
AD  - 4 Neuroscience Research, The University at Albany-SUNY, Albany, NY, USA.
AD  - 5 Biological Sciences, The University at Albany-SUNY, Albany, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20180110
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
RN  - 0 (5-alpha Reductase Inhibitors)
RN  - 0 (Estrogens)
RN  - 3XMK78S47O (Testosterone)
RN  - 57GNO57U7G (Finasteride)
SB  - IM
MH  - 5-alpha Reductase Inhibitors/*adverse effects/therapeutic use
MH  - Administration, Oral
MH  - Adult
MH  - Alopecia/*drug therapy
MH  - Cohort Studies
MH  - Estrogens/*metabolism
MH  - Exercise/physiology
MH  - Finasteride/*adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Psychology
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Self Report
MH  - Testosterone/*metabolism
PMC - PMC6131463
OTO - NOTNLM
OT  - androgens
OT  - cognitive performance
OT  - depression
OT  - sexual dysfunction
OT  - testosterone
COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2018/01/11 06:00
MHDA- 2019/06/14 06:00
PMCR- 2018/07/01
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/07/01 00:00 [pmc-release]
AID - 10.1177_1557988317750989 [pii]
AID - 10.1177/1557988317750989 [doi]
PST - ppublish
SO  - Am J Mens Health. 2018 Jul;12(4):900-906. doi: 10.1177/1557988317750989. Epub 
      2018 Jan 10.